All Insight, Analysis and Views

ViewPoints: Growth outlook for Pfizer's Ibrance set to decelerate
Ref: ViewPoints Desk
Tags: ViewPointsPfizer Lilly NovartisBreast Cancer Clinical Research (R&D)Ibrance Kisqali Verzenio
Spotlight On: What happened at ASCO this weekend...
Ref: Spotlight On Desk
Tags: Spotlight OnAstraZeneca Bristol Myers Squibb J&J Merck KGaA Pfizer Roche Clinical Research (R&D)ASCO
Arcus, Gilead look for shared spaces in I/O
Ref: ViewPoints Desk
Tags: ViewPointsGilead Arcus Biosciences RocheLung Cancer Clinical Research (R&D) Corporate Affairs LicensingAB154 zimberelimab
In anti-COVID fight, oral alternatives begin to take shape
Ref: ViewPoints Desk
Tags: ViewPointsGilead Merck & Co. Ridgeback Biotherapeutics Atea PharmaceuticalsCOVID-19 Clinical Research (R&D)Remdesivir EIDD-2801 AT-527
Friday Five – The pharma week in review (29 May 2020)
Ref: Friday Five Desk
Tags: Friday FiveMerck & Co. CanSino Biologics Gilead Regeneron Sanofi arGEN-X Alexion FDAClinical Research (R&D) Marketing & Sales Medical AffairsRemdesivir efgartigimod
Survey results: Oncologists busier than GPs as lockdowns are eased
Ref: Physician Views Desk
Tags: Physician Views Poll Results Medical Affairs
Added colour paints clearer picture of remdesivir's good-not-greatness
Ref: ViewPoints Desk
Tags: ViewPointsGilead Incyte LillyViral Infections FDAMarketing & Sales Medical Affairs Regulatory AffairsOlumiant Remdesivir
Ball is in Sunovion’s court to ensure a solid Kynmobi launch
Ref: ViewPoints Desk
Tags: ViewPointsAcorda Therapeutics Sumitomo Dainippon Sunovion US WorldMedsParkinson's FDAMarketing & Sales Medical Affairs Regulatory AffairsApokyn INBRIJA Kynmobi
argenx sees the finish line for FcRN
Ref: ViewPoints Desk
Tags: ViewPointsarGEN-X Alexion Clinical Research (R&D) Regulatory Affairsefgartigimod Soliris
Survey results: Country-level data shows disparity in recent adoption of telehealth
Ref: Physician Views Desk
Tags: Physician Views Poll Results Medical Affairs